The role of mesalamine in the treatment of ulcerative colitis

Therapeutics and Clinical Risk Management

Volumn 3, Issue 5, 2007, Pages 893-903

  Karagozian, Raffi ^a   Burakoff, Robert ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

5 ASA therapy; Inflammatory bowel disease; Mesalamine; Remission; Ulcerative colitis (UC)

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; AZATHIOPRINE; BALSALAZIDE; BECLOMETASONE; EUDRAGIT; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOTRIENE B4; LIPOXYGENASE; MESALAZINE; OLSALAZINE; PLACEBO; PROSTAGLANDIN SYNTHASE; SALAZOSULFAPYRIDINE; SALICYLIC ACID DERIVATIVE; STEROID; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ALOPECIA; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BLOATING; CANCER PREVENTION; CLINICAL FEATURE; CLINICAL TRIAL; COLON BIOPSY; COLON SURGERY; COLONOSCOPY; COLORECTAL CANCER; DERMATITIS; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG COATING; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVENING DOSAGE; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HEPATITIS; HUMAN; IMMUNOPATHOGENESIS; INTERSTITIAL NEPHRITIS; LEUKOPENIA; LIVER DYSFUNCTION; MAINTENANCE THERAPY; MYOCARDITIS; NAUSEA; NEPHROTOXICITY; OPTIMAL DRUG DOSE; PANCREATITIS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PERICARDITIS; PNEUMONIA; PROCTITIS; REMISSION; REVIEW; TERATOGENICITY; TOXIC MEGACOLON; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

EID: 36448938728     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Ardizzone S, Maconi G, Russo A, et al. 2005. Randomised controlled trial of azathioprine and 5-ammosalicylic acid for treatment of steroid dependent ulcerative colits. Gut, 55:47-53.
2. Bernstein CN, Blanchard IF, Kliewer, et al. 2001. Cancer risk in patients with inflammatory bowel disease: population based study. Cancer, 91:854-62.
3. Bernstein CN, Rawsthorne P, Cheang M, et al. 2006. A population-based case control study of potential risk factors for IBD. Am J Gastroenterol, 101:993-1002.
4. Bonen DK, Cho JH. 2003. The genetics of inflammatory bowel disease Gastroenterology, 124:521-36.
5. Bus PJ, Nagtegaal ID, Verspaget, et al. 1999. Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era? Aliment Pharmacol Ther, 13:1397-402.
6. Cohen RD. 2006. Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis. Aliment Pharmacol Ther, 24:465-74.
7. Cohen RD, Woseth DM, Thisted RA, et al. 2000. A Meta-analysis and overview of the Literature on Treatment Options for Left-Sided Ulcerative Colitis and Ulcerative Proctitis. Am J Gastroenterol, 95:1263-76.
8. Colombel IF, Brabant G, Gublrt MC, et al. 1994. Renal insufficiency in infant: Side effect of prenatal exposure to meslazine? Lancet, 344:620-1.
9. Cunliffe RN, Scott BB, et al. 2002. Monitoring for drug side-effects in inflammatory bowel disease. Aliment Pharmacol Ther, 16:647-62.
10. D'Arienzo A, Manguso F, Cimino L, et al. 1998. Beclomethasone dipropionate (3 mg) enemas combined with oral 5-ASAs (2.4g) in the treatment of ulcerative colitis not responsive to oral 5-ASA alone. Ital J Gastroenterol Hepatol, 30:254-7.
11. Diav-Citran O, Park YW, Veerasuntharan G, et al. 1998. The safety of Mesalamine in Human Pregnancy: A Prospective Controlled Cohort Study. Gastroenterology, 114:23-8.
12. Egan LJ, Mays DC, Huntoon CJ, et al. 1999. Inhibition of interleukin-1-stimulated NF-kappaB Re1A/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem, 274:448-53.
13. Fiocchi C. 1999. Inflammatory bowel disease: etiology and pathogenesis: Gastroenterology, 115:182-205.
14. Frieri G, Pimpo M, Galletti, et al. 2005. Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis. Digestive and Liver Disease, 37:92-6.
15. Grisham, MD. 1994. Oxidants and free radicals in inflammatory bowel disease. Lancet, 344:859-61.
16. Hanauer SB. 2004. Review article: aminosalicylates in inflammatory bowel ulcerative colitis. Aliments Pharmacol Ther, 20:(Suppl 4)60-5.
17. Hanauer SB, Sandborn WJ, Kornbluth A, et al. 2005. Delayed-release oral mesa] amine at 4.8 g/day (800 mg tablet) for the treatment of moderately active disease. Ascend II Trial. American Journal of Gastroenterology, 100:2478-85.
18. Kaiser GC, Yan F, Polk DB, et al. 1999. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology, 116:602-9.
19. Kane SV, Bjorkman DJ. 2003. The efficacy-of oral 5-ASAs in the treatment of active ulcerative colitis: A Systematic Review. Reviews in Gastroenterological Disorders, 3:210-18.
20. Kombluth A, Sachar D. 2004. Ulcerative Colitis Practice Guidelines in adults (Update): American College of Gastroenterology, Practice Parameters Conunittee. American Journal of Gastroenerology, 1372-85.
21. Loftus EV, Silverstein Sandborn WJ, et al. 2000. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survivial. Gut, 46:336-43.
22. Loftus EV, Kane SV, Bjorkman D, et al. 2003. Systematic review: short-term adverse effects of 5-aminosalicylic acid in the treatment of ulcerative colitis. Aliment Pharmacol Ther, 19:179-89.
23. Mansfield JC, Giaffer MH, Cann PA, et al. 2002. A double-blind comparison of balsalazide, 6.75 g and sulfasalazine, 3 g as sole therapy in the management of ulcerative colitis. Aliment Pharmacol Ther, 16:69-77.
24. Marshall JK, Irvine EJ. 1995. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta analysis. Aliment Pharmacol Ther, 9:293-300.
25. Marteau PH, Probert CS, Lindgren M, et al. 2005. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomized, double blind placebo controlled study. Gut, 54:960-5.
26. Marteau PH, Crand J, Foucault M, et al. 1998. Use of mesalazine slow release suppositories 1 gm three times per week to maintain remission of ulcerative proctitis: a randomized double blind placebo controlled multicentre study. Gut, 42:195-9.
27. Marteau PH, Seksik, Beaugerie, et al. 2004. Recommandations pour la pratique clinique pour le traitment de la rectocolite hemorragique. Gastroenterol Clin Biol, 28:955-60.
28. Misiewicz JJ, Lennard, Jones JE, et al. 1965. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet, 1965 1:185-8.
29. Orholm M, Munkholm P, Langholz E, et al. 1991. Familial occurrence of inflammatory bowel disease. N Eng J Med, 324:84-8.
30. Paoluzi OA, lacopini F, Pica P, et al. 2005. Comparison of two different daily dosages (2.4 vs 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1 -year follow-up study. Aliment Pharmacol Ther, 21:1111-9.
31. Podolosky DK, 2002. Inflammatory Bowel Disease. N Eng J Med, 347:417-29.
32. Powell-Tuck J, Truelove SC. 1963. The course and prognosis of ulcerative colitis. Gut, 4:299-315.
33. Powrie F. 1995. T-cells in inflammatory bowel disease: protective and pathogenic roles. Immunity, 3:171-4.
34. Prantera C, Viscido A, Biancone L, et al. 2005. A new oral delivery system for 5-ASA: preliminary clinical findings for MMX. Inflamm Bowel Dis, 11:421-7.
35. Pruitt R, Hanson J, Safdi M, et al. 2002. Balsalazide is superior to mesalamine in time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am J Gastroenterol, 97:3078-86.
36. Ransford RA, Langman MJ, et al. 2002. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut, 51:536-9.
37. Rochester J, Abreu MT. 2005. Ulcerative Colitis Therapy: Importance of Delivery Mechanisms. Reviews in Gastroenterological Disorders, 5:215-22.
38. Reinacher-Schick A, Seidensticker F, Petrash S, et al. 2000. Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel. Endoscopy, 32:245-54.
39. Rubin DT, LoSavio A, Yardon N, et al. 2006. Aminosalicylate Therapy in the Prevention of Dysplasia and Colorectal Cancer in Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 4:1346-50.
40. Safdi M, DeMicco M, Sninsky CA, et al. 1997. A double-blind comparison of oral versus rectal mesalamine combination therapy in treatment of distal ulcerative colitis. Am J Gastroenterol, 92:1867-71.
41. Schroeder KW, Tremaine WJ, Ilstrup, et al. 1987. Coated oral 5-aminosalicylic acid therapy for mild to moderately active ulcerative colitis. N Engl J Med, 17:1625-9.
42. Shanahan F. 2001. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology, 120:622-35.
43. Sninsky CA, Cort DH, Shanahan F, et al. 1991. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter trial. Ann Intern Med, 115:350-5.
44. Stenson WF, Korzenik W 2003. Inflammatory Bowel Disease. In Yamata T. Textbook of Gastroenterology. 4th ed. Lippincott Williams and Wilkins. p. 1699-759.
45. Strober W, Ludviksson BR, Fuss IJ, et al. 1998. The pathogenesis of mucosal inflammation in murine models of inflammatory bowel disease and Crohn's disease. Ann Intern Med, 128:848-56.
46. Sutherland L, Macdonald JK. 2006. Oral 5-aminosalicylates for induction of remission in ulcerative colitis. Cochrane Database.
47. van Staa TP, Card T, Logan RF, et al. 2005. 5-Ammosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut, 54:1573-8.
48. Velayos FS, Terdiman JP, Walsh JM, et al. 2005. Effect of 5-ammosalicylastes use on colorectal cancer and dysplasia risk: a systematic review and meta-analysis of observational studies. Am J Gastroenterol, 100:1345-53.